Normal or enhanced short‐latency afferent inhibition in Parkinson’s disease?
Open Access
- 1 April 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 127 (4) , e8
- https://doi.org/10.1093/brain/awh089
Abstract
Sailer and colleagues (2003) evaluated short‐ and long‐latency afferent inhibition in patients with Parkinson’s disease. They reported that short‐latency afferent inhibition (SAI) is normal in Parkinson’s disease off dopaminergic medication, but that it is reduced in the more affected side in Parkinson’s disease on medication. Figure 2 of the paper mentioned above shows a tendency to more pronounced SAI in the more affected side of Parkinson’s disease patients than in control subjects and that this tendency is reversed by l‐dopa administration. Therefore, a different possible explanation of their findings is that SAI is pathologically increased in Parkinson’s disease patients and that l‐dopa administration restores it.Keywords
This publication has 6 references indexed in Scilit:
- Short and long latency afferent inhibition in Parkinson's diseaseBrain, 2003
- Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortexExperimental Brain Research, 2000
- Short latency inhibition of human hand motor cortex by somatosensory input from the handThe Journal of Physiology, 2000
- Altered Muscarinic and Nicotinic Receptor Densities in Cortical and Subcortical Brain Regions in Parkinson's DiseaseJournal of Neurochemistry, 1993
- Different forms of brain acetylcholinesterase and muscarinic binding in Parkinson's diseaseJournal of the Neurological Sciences, 1989
- Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementiaBrain Research, 1982